Viewing 1 post (of 1 total)
  • Author
  • #4718
    Expert Nurse
    Lisa Kottschade

    I am curious what your practices might be doing in terms of choice of therapy with a 3rd in class BRAF/MEK inhibitor combo likely coming to market very soon? What factors would sway you to one product over another?

    Also- do you think this will help to drive down cost of these oral agents?

    Looking forward to everyone’s insights.

Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.